| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BACKGROUND: The intrathoracic pressure regulator (ITPR) plus positive pressure ventilation (PPV) has been shown to improve coronary and cerebral perfusion pressures during hypovolemia by improving mean arterial blood pressure and by decreasing right atrial and intracranial pressures. We hypothesized that application of intermittent negative intrathoracic pressure in a pig model of severe hypovolemic hypotension would increase 24-h neurological intact survival rates. METHODS: Eighteen isoflurane-anesthetized pigs were bled 55% of their estimated blood volume and were then prospectively randomized to either ITPR treatment with 8 mm Hg endotracheal pressure plus PPV or only PPV alone for 90 min. All survivors were reinfused with their own blood. Arterial blood gases, end-tidal CO2, and aortic pressures were monitored for the 90 min and neurological evaluation was performed at 12 and 24 h after reinfusion. RESULTS: ITPR plus PPV treatment for 90 min prevented the progression of metabolic acidosis and significantly improved mean arterial blood pressure (mean over 90 min, 55 ± 3 vs 35 ± 2.4 mm Hg, P < 0.001) when compared with controls. Twenty-four hour survival significantly improved with use of the ITPR when compared with untreated controls: 9/9 (100%) vs 1/9 (11%), P < 0.01. CONCLUSIONS: Use of the ITPR plus PPV for 90 min significantly increased arterial blood pressure and 24 h neurologically intact survival rates compared with controls treated with PPV alone.
Enhancement of the intrathoracic vacuum during spontaneous inspiration has been recently shown to improve hemodynamics in states of hypovolemic hypotension in spontaneously breathing animals and humans (17). With inspiration against a low level of resistance, an intrathoracic vacuum is created that enhances venous blood flow back to the heart and decreases intracranial pressures (6,7). A similar physiological approach has demonstrated to improve survival rates in cardiac arrest with an inspiratory impedance threshold device (ITD). The ITD impedes the influx of respiratory gases during the chest wall recoil phase of cardiopulmonary resuscitation, thereby enhancing venous return and vital organ circulation (613). In an effort to use a similar strategy to intermittently decrease intrathoracic pressures to enhance venous blood flow back to the heart and to decrease intracranial pressures in patients requiring assisted ventilation, an intrathoracic pressure regulator (ITPR) was developed (14). This new device has been recently shown to increase survival rates in pigs in cardiac arrest and to improve hemodynamics in apneic animals during hypovolemic hypotension (14,15). In the hypotensive pigs, there was a dose effect: intermittent application of an intrathoracic vacuum generated a greater hemodynamic benefit down to approximately 10 mm Hg, and the largest benefit was observed in the most hypotensive animals (50% blood loss) (14). Building on the basic physiological principles discovered in these earlier studies, the purpose of the current investigation was to evaluate the effectiveness of the ITPR, designed to regulate intrathoracic pressures in nonbreathing animals during severe hypovolemic hypotension. We hypothesized that application of the ITPR in a porcine model of severe but controlled blood loss would result in improved mean arterial blood pressure (MAP) and neurologically intact survival rates compared with untreated controls. The results have potential implications for the treatment of intraoperative hypotension and traumatic injury.
The Institutional Animal Care Committee of the Minneapolis Medical Research Foundation at Hennepin County Medical Center approved the studies. All animals received treatment and care in compliance with the 1996 Guide for the Care and Use of Laboratory Animals by the National Research Council in accord with the USDA Animal Welfare Act, PHS Policy, and the American Association for Accreditation of Laboratory Animal Care. The study protocol can be summarized as follows. After an acute 55% blood loss and 5 min of stabilization, 18 pigs were prospectively randomized to either the ITPR intervention group, with the ITPR set to maintain intrathoracic pressures of 8 mm Hg between positive pressure ventilations (PPV), or the control group treated only with PPV. After 90 min, surviving animals received IV fluid (blood) resuscitation and were followed for 24-h to evaluate survival and neurological outcomes.
Preparatory Phase A 4F femoral artery sheath was placed under aseptic conditions. A Millar catheter was used to continuously measure central aortic pressure. Arterial blood gases were collected from the sheath. Surface electrocardiogram was also monitored continuously. All data were digitized using a computerized data analysis program (Superscope II vl.295, GW Instruments, Somerville, MA) and a Power Macintosh G3 ® computer (Apple Computer, Inc., Cupertino, CA). ETco2, tidal volume, and arterial oxygen saturation were recorded with a CO2SMO Plus®, (Novametrix Medical Systems, Wallingford, CT). MAP was electronically calculated from the electronic waveforms in the recording system.
Device Description
Protocol
Statistical Analysis
The average weight of all animals was 28 ± 1.2 kg, and there were no differences in weight or age between groups (approximately 1416 wk old). The average blood loss in the control group was 890 ± 89 mL, and in the ITPR group was 904 ± 93 mL (P = NS). After 55% blood withdrawal, the application of a negative airway pressure of 8 mm Hg resulted in a significant increase in MAP for the entire 90 min of treatment when compared with the control group, P < 0.01 (Figs. 1 and 2). MAP returned to normal (83 ± 13 mm Hg) after blood reinfusion at 90 min. Heart rate (sampled every 15 min and averaged) was significantly lower in the ITPR+PPV group throughout the study when compared with PPV only group, 151 ± 13 vs 182 ± 19 bpm, P < 0.01.
Nine animals survived to blood reinfusion at 90 min in the ITPR treatment group, and only two animals survived in the control group. After 24 h all animals were alive in the ITPR group, but only 1/9 (11%) was alive in the control group, P < 0.01. One of the two survivors from the control group was found dead in the cage 16 h later. Eight of nine animals in the ITPR group had normal neurological function after 12 and 24 h, and 1/9 had a Cerebral Performance Score of 3 at 12 h and 4 at 24 h. The sole survivor in the control group had a Cerebral Performance Score of 2 at 12 h and normal neurological function after 24 h. Arterial blood gases showed progressive metabolic acidosis with increasing base deficit in the control group, whereas in the ITPR group, metabolic acidosis was maintained to a level compatible with life (Fig. 3). The only two animals that survived the 90 min period of time in the control group had a less severe metabolic acidosis compared to the rest of the control group animals. There was a significant increase in ETco2 throughout the 90 min of the ITPR application when compared with the control group (Fig. 3). The difference between Paco2 and ETco2 has been consistently lower in the ITPR group as well. Oxygenation was adequate in both groups without significant differences (Fig. 3).
It has been recently shown that use of the ITPR and intermittent PPV in pigs subjected to severe blood loss improves key physiological variables, decreases intracranial pressure and improves vital organ perfusion pressures (14). Building on those findings, this study focused on survival after a severe bleed. The results demonstrate that prolonged application of ITPR and intermittent PPV during hypovolemic hypotension increased MAP and survival rates compared with untreated controls. The data support the hypothesis that use of the ITPR may be of benefit to increase survival rates by enhancing perfusion pressures and preventing the development of severe metabolic acidosis in the setting of severe hypotension. This is the first time the ITPR has been shown increase survival rates after severe hemorrhage. The application of the ITPR to generate 8 mm Hg ETP resulted in an immediate increase in MAP. An earlier study showed that this device instantaneously decreases intracranial and right atrial pressures, which results in an immediate increase in coronary and cerebral perfusion pressures in pigs with severe hypovolemia (14). It is likely that the improved vital organ perfusion helped, in the current study, to prevent life-threatening metabolic acidosis in the ITPR-treated group. Higher ETco2 may also reflect better tissue perfusion and greater CO2 clearance, whereas a decrease in Paco2ETco2 supports better ventilation/perfusion matching (14). The ITPR was set to 8 mm Hg of ETP for the survival study based on an earlier study where 10 mm Hg was used (14) and pilot studies demonstrating that animals tolerated this dose for up to 6 h without changes in oxygenation or acid base balance. The hemodynamic benefits appear to plateau around 8 to 10 mm Hg. To have the maximum effect with the smallest risk for pulmonary complications, an intrathoracic vacuum set to 8 mm Hg was used in this survival study. Although there may be greater benefit using lower pressures, pulmonary complications may be more frequent. This issue requires further characterization and investigation. In the control group, profound acute volume depletion resulting in severe progressive metabolic acidosis was observed simultaneously with the high death rate. The ITPR prevented the downward spiral of metabolic acidosis suggesting that a potential application of the new device could be to buy time in clinical scenarios when immediate intravascular fluid resuscitation is not possible, as long as active bleeding is controlled. Thus, the technology may be helpful in the treatment of traumatic injuries outside of the hospital. In addition, it is possible that the ITPR may be of clinical value in treating intraoperative hypovolemic hypotension in intubated, anesthetized patients, especially when treatment with vasopressors or fluids is relatively contraindicated. Longer duration studies will be required to determine the potential value of the ITPR in these clinical settings before alternative therapies, such as surgery, intravascular fluid resuscitation, or vasopressor drugs, are required. There are limitations in this study. First, we did not measure actual vital organ blood flow. Nonetheless, the effects on perfusion pressures and survival observed in this study with the use of the ITPR suggest that blood flow was significantly higher in the treated group. Second, our model of fixed severe hypovolemic hypotension cannot be generalized to uncontrolled bleeding where the ITPR could potentially worsen the blood loss. Third, we evaluated only one negative ETP: the optimal negative ETP resulting in maximum benefit at minimal risk needs to be better characterized and investigated. Finally, we used the anesthetic isoflurane in this study without measuring exhaled concentrations. Other drugs we have used previously, such as propofol, have known vasodepressor effects and can cause metabolic acidosis, cardiodepression, and neuroprotection with prolonged use (2025). Isoflurane has the fewer side effects and is among the least cardiodepressive drug among the commonly used anesthetics (26). Thus, although it possible, it is not likely that the anesthetic may have influenced the outcome of this study. Finally, the survival rate in the control group precludes definite neurological comparisons between groups. A larger study is underway.
Use of the ITPR during severe hypovolemic hypotension, resulted in 1) a significant improvement in MAP and ETco2, 2) stabilization of the metabolic effects of systemic hypoperfusion, and 3) a significant improvement in neurologically intact 24-h survival rates when compared with controls in this porcine model of fixed volume hypovolemic hypotension.
Accepted for publication September 25, 2006. Supported by American Heart Association Postdoctoral Fellowship Grant 0425714Z, National Institute of Health SBIR Grant R44 HL08208801, and the Dwight Opperman Foundation. Disclosures: Dr. Keith Lurie is a co-inventor of the intrathoracic pressure regulator used in this study and founded a company, Advanced Circulatory Systems Incorporated (ACSI) to develop and commercialize this technology. Dr. Anja Metzger is employed by Advanced Circulatory Systems.
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|